Silymarin ameliorates expression of urotensin II (U-II) and its receptor (UTR) and attenuates toxic oxidative stress in the heart of rats with type 2 diabetes

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Rahimeh RahimiFatemeh Goli

Abstract

Type 2 diabetes mellitus (T2DM) is associated with an increased risk of cardiovascular disease (CVD). Urotensin II ((U-II)) and its receptor (UTR) are involved in the progression of CVD through enhancement in the production of reactive oxygen species (ROS). Since silymarin (SMN) is a natural agent with anti-diabetic effects, this study aimed to investigate the antioxidant potency of SMN on the expression of (U-II)/UTR system and oxidative stress status in the heart of type 2 diabetic rats. Thirty-six male Wistar rats were randomly divided into six groups (n = 6). Control and diabetic groups treated with or without SMN (60 and 120 mg/kg/day) for 2 months. Fasting blood sugar (FBS), insulin, lipid profile, creatine kinase-MB ((CK-MB)), lactate dehydrogenase (LDH) and markers of oxidative stress were measured by spectrophotometric methods while (U-II) and UTR gene expression was determined by qPCR method. SMN significantly reduced the FBS level, increased the concentration of insulin and improved HOMA-IR. SMN prevented diabetes-induced weight loss, and attenuated the increased levels of total oxidative status (TOS), malondialdehyde (MDA), and nitric oxide (NO). Diabetes-induced reduction of total thiol molecules content (TTM) was ...Continue Reading

References

Jan 1, 1994·Methods in Enzymology·M L Hu
Sep 15, 1999·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·J Pepping
Sep 21, 2002·Lancet·A Mark RichardsTimothy G Yandle
Dec 4, 2002·Circulation·Leong L NgJoan E Davies
Oct 11, 2005·Clinical Biochemistry·Ozcan Erel
Feb 24, 2006·Toxicology and Applied Pharmacology·Anabela P Rolo, Carlos M Palmeira
Dec 5, 2006·Current Hypertension Reports·Nicolas Bousette, Adel Giaid
Oct 13, 2007·Peptides·Jérôme LeprinceHubert Vaudry
Aug 2, 2008·European Journal of Pharmacology·Yen-Ling ChenTzu-Hurng Cheng
Dec 11, 2008·Vascular Health and Risk Management·Fraser D Russell
Aug 4, 2011·Frontiers in Pharmacology·Philip TsoukasAdel Giaid
Jan 1, 2010·Journal of Laboratory Physicians·Lorenzo GordonE Martorell
Oct 26, 2011·Journal of Pharmacology & Pharmacotherapeutics·Manonmani Alvin JoseM P Narmadha
Dec 6, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Stephen J PolyakJean-Michel Pawlotsky
Apr 10, 2013·Asian Pacific Journal of Tropical Biomedicine·Subramaniam RamachandranK T Manisenthilkumar
Mar 29, 2014·Arteriosclerosis, Thrombosis, and Vascular Biology·Shohei IkedaHiroaki Shimokawa
Jun 13, 2014·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Daniel Lorber
Jul 23, 2014·PloS One·Klinsmann Carolo dos SantosAna Angélica Henrique Fernandes
Dec 20, 2014·Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·Ernst E van der Wall
Jun 6, 2015·International Journal of Molecular Sciences·Hui GongYunzeng Zou
Sep 30, 2015·Journal of Diabetes Investigation·Wan-Yu HeAi-Hua Zhang
Jun 25, 2016·Journal of Diabetes Research·Luminita VoroneanuAdrian Covic
Oct 17, 2016·Biological Trace Element Research·Soheila AsadiMarzieh Mahmoodi
Jul 8, 2017·Evidence-based Complementary and Alternative Medicine : ECAM·Xinqi ChengZhiwu Chen
Nov 2, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Ebrahim ZarrinkalamAlireza Komaki

❮ Previous
Next ❯

Citations

Jan 3, 2019·The Journal of Endocrinology·Sui-Lin Sun, Liang-Ming Liu
Mar 7, 2020·Journal of Basic and Clinical Physiology and Pharmacology·Fernanda Caetano Camini, Daniela Caldeira Costa
Jul 7, 2018·Archives of Pharmacal Research·Chun ChuFanxing Xu
Sep 2, 2020·Journal of Ethnopharmacology·Sadegh ShababMaryam Mahmoudabady
Aug 31, 2021·The Kaohsiung Journal of Medical Sciences·Jing-Guo MaLin Zha
Sep 23, 2021·Experimental Biology and Medicine·Faten ZahranNabila Zein
Sep 17, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Aline Maria StolfAlexandra Acco

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Diabetes

This feed focuses on the latest research on biomarkers used for monitoring disease progression in diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cajal Bodies & Gems

Cajal bodies or coiled bodies are dense foci of coilin protein. Gemini of Cajal bodies, or gems, are microscopically similar to Cajal bodies. It is believed that Cajal bodies play important roles in RNA processing while gems assist the Cajal bodies. Find the latest research on Cajal bodies and gems here.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.